Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sernova Corp SEOVF


Primary Symbol: T.SVA

Healthcare Biotechnology
Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch... see more

Recent & Breaking News (TSX:SVA)

Sernova Receives Conditional Approval to Up-list to the Toronto Stock Exchange

TheNewsWire May 24, 2022

Sernova (TSXV:SVA) enters partnership to develop and commercialize infinite insulin therapy

Caroline Egan  May 17, 2022

Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a 'Functional Cure' for Diabetes

GlobeNewswire May 17, 2022

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 82nd Scientific Sessions 2022

TheNewsWire May 9, 2022

Sernova to Participate in Multiple U.S. Healthcare Investor Conferences

TheNewsWire May 5, 2022

Sernova Announces 2022 Annual General Meeting Results

TheNewsWire April 29, 2022

Data Safety Monitoring Board Recommends Continuation of Phase 1/2 Clinical Trial with Sernova's Cell Pouch System(TM) in Patients with Type-1 Diabetes

TheNewsWire March 17, 2022

Sernova Corp Ranks Among Top 50 Performing Companies on the 2022 TSX Venture List

TheNewsWire February 24, 2022

Sernova Announces Peer Reviewed Publication Demonstrating Positive Preclinical Safety and Efficacy Indicators of Its Novel Cell Pouch System(TM) Therapeutic Approach for Treatment of Thyroid Disease

TheNewsWire January 27, 2022

Sernova Announces Peer Reviewed Publication Demonstrating Safety and Efficacy of a Novel Cell Pouch Cell Therapy Approach for Treatment of Severe Hemophilia A

TheNewsWire January 20, 2022

IIROC Trading Resumption - SVA

PR Newswire January 10, 2022

IIROC Trading Halt - SVA

PR Newswire January 10, 2022

The Principal Investigator in Sernova's Type 1 Diabetes (T1D) Trial Confirms Patients with a History of Hypoglycemia Unawareness Are Now Insulin Independent

TheNewsWire January 10, 2022

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

TheNewsWire January 5, 2022

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

TheNewsWire December 16, 2021

Sernova Appoints Christopher Barnes as Vice President, Investor Relations & Grants Options/DSUs

TheNewsWire December 14, 2021

Sernova Announces Appointment of Executive Chair to Complement its Management Team

TheNewsWire December 2, 2021

Sernova to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

TheNewsWire November 16, 2021

Sernova: The Ultimate Combination of Two Proven Technologies as Potential Functional Cure for Type 1 Diabetes and Other Chronic Diseases

TheNewsWire October 1, 2021

Sernova Engages New York-Based LifeSci Advisors as US Investor Relations Partner

TheNewsWire September 29, 2021